Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A Dimopoulos,Sebastian Grosicki,Wieslaw W Jedrzejczak,Hareth Nahi,Astrid Gruber,Markus Hansson,Catriona Byrne,Richard Labotka,Ai-Min Hui,Zhaoyang Teng,Norbert Grzasko

doi:10.1182/blood.v126.23.26.26

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A Dimopoulos, Sebastian Grosicki + Show 9 more

https://doi.org/10.1182/blood.v126.23.26.26

Copy DOI

Journal: Blood	Publication Date: Dec 3, 2015
Citations: 10

Affiliation: National and Kapodistrian University of Athens, Medical University of Silesia, University of Warsaw, Karolinska University Hospital, Skåne University Hospital, Takeda (United States), Millennium Engineering and Integration (United States), Medical University of Lublin

#Investigational Proteasome Inhibitor Ixazomib #Pts In Arm + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Full Text